A Controlled Double-Blind Study of Piracetam in the Treatment of Senile Dementia

Dencker, Doc Sven Sven J.; Lindberg, D.

doi:10.3109/08039487709106730

Cited by 9 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Piracetam (2.4 to 9.5 g/day) did not significantly differ from placebo in 6 controlled trials, including in the final analysis a mean of 28 geriatric patients with senile dementia, chronic or acute cerebral ischaemia and elderly patients with mild deterioration of mental function (Abuzzahab et ai., 1978;Dencker and Lindberg, 1977;Diesfeldt et ai., 1978;Gedye et ai., 1978;Gustafson et ai., 1978;Trabant et ai., 1977).…”

Section: Clinical Studiesmentioning

confidence: 99%

???Cerebroactive??? Drugs Clinical Pharmacology and Therapeutic Role in Cerebrovascular Disorders

Spagnoli

Tognoni

1983

Drugs

View full text Add to dashboard Cite

While their importance in the market-place is steadily increasing in developed (mainly continental Europe) and even in developing countries, compounds included in the broad category of 'cerebroactive' drugs hardly rate a mention in reference pharmacology and therapeutics textbooks. It is an undeniable fact, however, that the principal users or targets of this drug class, mainly elderly people, represent an increasingly worrying problem, with their often puzzling cohort of ill-definable and even less predictable neurological and mental symptoms. The combination of the above factors cannot but produce a rather confused situation, in which the pressure to treat and the adherence to scientifically rigorous assessment are likely to prevail alternately, on a purely casual basis. This review aims to provide sound methodological guidelines for assessment of 'cerebroactive' drugs in a not always easily accessible literature. It covers firstly the general problems of stroke, dementia and 'common symptoms' of the elderly, and then looks in detail at those compounds which have to date attracted most attention (ergot derivatives, cinnarizine, flunarizine, vincamine, eburnamonine, naftidrofuryl, oxpentifylline, piracetam and citicoline), as well as those which are currently considered investigational (choline and lecithin). The pharmacology and available clinical studies of each drug are examined. No therapeutic indication can be derived from the available evidence, as the few positive results do not go beyond random improvement of symptoms. More fundamentally, the lines of research which need to be pursued most intensively relate to better preliminary definition of diagnostic and prognostic criteria and, with the establishment of adequate testing tools for the assessment of behaviour and neuropsychological performance, those basal conditions which are modified 'naturally' or by drugs.

show abstract

Section: Clinical Studiesmentioning

confidence: 99%

???Cerebroactive??? Drugs Clinical Pharmacology and Therapeutic Role in Cerebrovascular Disorders

Spagnoli

Tognoni

1983

Drugs

View full text Add to dashboard Cite

show abstract

“…The latter drug has been used as a nonstimulant drug for the treatment of reduced alertness and impaired memory function in elderly patients. Several studies have shown piracetam to be more effective than placebo [Stegink, 1972;Kretschmar and Kretschmar, 19761; whereas in other studies [Dencker and Lindberg, 1977;Gustafson ct al., 19783 no significant effect of the drug was found.…”

Section: Introductionmentioning

confidence: 99%

Some neurochemical properties of pramiracetam (CI‐879), a new cognition‐enhancing agent

Pugsley

Shih

Coughenour

et al. 1983

Drug Development Research

View full text Add to dashboard Cite

The present study was initiated to examine the effect of pramiracetam sulfate [N-[B[bis(lrnethylethyl)amino]ethyl]-2 oxo-l-pyrrolidineacetamide sulfate (1 :1)] (PR), a new cognitionactivator agent, on various neurochemical parameters in order to gain some insight into the mechanism of action of this agent. PR (100 mg/kg i.p.) did not alter the concentration of norepinephrine, dopamine (DA), serotonin (5-HT), 5-hydroxyindoleacetic, and homovanillic acid in various brain areas. The agent also did not alter d-methamphetamine-induced changes in monoarnine metabolism nor prolactin concentration in rat serum. PR did not exhibit any affinity in vitro for doparninergic, adrenergic, serotoninergic, GABAergic, muscarinic, adenosine (ICs0 > 10 pM), and benzodiazepine receptors (ICs0 > 1 pM) binding sites. It may be concluded that the mechanism of action of pramiracetam does not appear to be due to a direct action upon DA and 5-HT neurotransmitter systems or various brain receptors. PR (44 and 88 mglkg i.p.) caused a significant increase in the rate of sodiumdependent high-affinity choline uptake (HACU) into rat hippocampal synptosomes in vitro. This was specific as no effect was observed in cerebral cortex and corpus striaturn. These results would seem to indicate that PR is accelerating hippocampal acetylcholine turnover and thus septal-hippocampal cholinergic neuronal impulse flow. This effect could be at least partially responsible for the enhancement of cognition processes observed for this agent.

show abstract

Pharmacologic Approaches to Gerontopsychiatry

Loew¹,

Vigouret²

1981

Psychotropic Agents

View full text Add to dashboard Cite

A Controlled Double-Blind Study of Piracetam in the Treatment of Senile Dementia

Cited by 9 publications

References 2 publications

???Cerebroactive??? Drugs Clinical Pharmacology and Therapeutic Role in Cerebrovascular Disorders

???Cerebroactive??? Drugs Clinical Pharmacology and Therapeutic Role in Cerebrovascular Disorders

Some neurochemical properties of pramiracetam (CI‐879), a new cognition‐enhancing agent

Pharmacologic Approaches to Gerontopsychiatry

Contact Info

Product

Resources

About